Sapphiros
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.
Top Stages
2 past transactions
Flexotronix
Acquisition in 2022
Flexotronix is a privately held Innovation and manufacturing company focused on developing high-volume manufacturing technologies and flexo-printed electronics
BioCrucible
Acquisition in 2021
BioCrucible is focused on advancing diagnostics through innovative technologies that leverage biomolecular condensate formation. The company is developing a highly sensitive and specific molecular diagnostic product aimed at addressing health challenges in underdeveloped countries, particularly for testing and treating infectious diseases. By utilizing a proprietary molecular technology platform, BioCrucible enhances the behavior and kinetics of engineered biological systems, enabling the creation of next-generation diagnostic tools that can improve health outcomes in resource-limited settings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.